Some of the names on the move ahead of the open.» Read More
Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.
Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.
Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.
Some of Monday's midday movers:
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.
P&G is working with advisers to review up to 100 underperforming brands for potential divestiture.
LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.
Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.
Take a look at some of Thursday's midday movers:
*Cisco down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures pointed to a flat open on Thursday as investors found few reasons to buy following a sharp rally in the previous session and amid signs of weakness in Europe and ongoing uncertainty over Ukraine.
*Cisco shares down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures edged higher on Thursday, with investors reluctant to make big bets following a sharp rally in the previous session and amid signs of weak conditions in Europe. *Cisco Systems Inc fell 1.3 percent to $24.87 in premarket trading.
U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.
European shares were higher on Wednesday, helped along by a rally in the insurance sector, as investors remained focused on geopolitical tensions.
These 20 S&P 500 companies reported effective tax rates of 0% or lower in the second calendar quarter, despite reporting a profit during the period.
The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.
Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.
NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
*Advair restored to Express Scripts 2015 formulary list. LONDON, Aug 4- GlaxoSmithKline received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015..